Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2026)

Arcus Biosciences has reported Other Non-Current Liabilities for 10 years, with the latest figure at $119.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 28.31% year-over-year to $119.0 million; the trailing twelve-month figure through Mar 2026 stood at $119.0 million (down 28.31% YoY), and the FY2025 full-year result was $135.0 million, down 14.01% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $119.0 million, down from $135.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $166.0 million in Q1 2025, with the low at $13.9 million in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is $121.3 million, with a median of $140.0 million recorded in 2022.
• Year-over-year, Other Non-Current Liabilities soared 945.12% in 2023 and declined 28.31% in 2026.
• Tracing RCUS's Other Non-Current Liabilities over 5 years: stood at $140.0 million in 2022, then increased by 1.43% to $142.0 million in 2023, then gained by 10.56% to $157.0 million in 2024, then retreated by 14.01% to $135.0 million in 2025, then fell by 11.85% to $119.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $119.0 million (Q1 2026), $135.0 million (Q4 2025), and $152.0 million (Q3 2025), per Business Quant data.

Peer Comparison